<i>In vitro</i> and physiologically‐based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin

Abstract

In vitro DDI followed by a predictive or PBPK approach was applied to determine DDI potential of canagliflozin. Overall, canagliflozin is neither a perpetrator nor a victim of clinically important interactions.